Home » Topics » Disease categories and therapies » Urology

Urology
RSS

Phase III AMPLIFY study of phosphate absorption inhibitor tenapanor meets primary endpoint

Sep. 4, 2019

Eli Lilly and Company describes PDE1 inhibitors

Sep. 3, 2019

Discovery and preclinical evaluation of SH-379 as a novel anti-LOH agent

Aug. 22, 2019

Initiator Pharma provides an update on IPED-2015 and IP-2018 development

Aug. 16, 2019

SHR-1653 as a novel highly potent and selective OTR antagonist

Aug. 14, 2019

Eloxx Pharmaceuticals initiates phase II study for ELX-02 in cystinosis

Aug. 6, 2019

Aronora opens phase II study of AB-002 in end-stage renal disease patients on chronic hemodialysis

Aug. 1, 2019

Roystonea regia lipid extract reduces lower urinary tract symptoms in men with BPH

July 26, 2019

Regulus outlines FDA requirements to reinitiate MAD studies with RGLS-4326

July 24, 2019

BioMarin Pharmaceutical identifies hydroxyacid oxidase 1 inhibitors

July 24, 2019

Popular Stories

Today's news in brief
BioWorld
Inhibiting the NLRP3 inflammasome for cognitive impairment, stroke
BioWorld Science
Vascular cognitive impairment and dementia (VCID) and cerebral small vessel disease are among the leading causes of dementia, where inflammation is known to play...
New mechanism of action identified for QC-6352
BioWorld Science
QC-6352 is a small molecule developed to inhibit the histone demethylase 4 (KDM4) that has shown potent antitumoral activity and which has a derivative named...
First-in-class pan-inflammasome blocker for hidradenitis suppurativa
BioWorld Science
Researchers from Paratus Sciences Corp. presented the preclinical profile of PS-1001, a novel pan-inflammasome inhibitor designed to prevent IL-1β and IL-18 release.
SCAN is core circuit affected in Parkinson’s disease
BioWorld
Parkinson’s disease is a neurodegenerative disorder that affects movement, and tremor is one of its signatures. But it is a much more wide-ranging disorder, and...